BrightGene Bio-Medical Technology Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2001

Location

Suzhou Jiangsu China

Primary Industry

Pharmaceuticals

About

Established in 2001 and based in Suzhou, China, BrightGene Bio-Medical Technology Co., Ltd. operates as an API and preparation developer that mainly provides original new drugs. In January 2019, it raised CNY 550 million of pre-IPO funding led by new investors HighLight Capital and Sequoia Capital. In November 2019, BrightGene Bio-Medical Technology Co., Ltd. was listed on the Shanghai Stock Exchange. The company mainly provides API and preparation drugs. The product line covers multiple therapeutic areas such as antiviral, antifungal, immunosuppressive, anti-tumor, cardiovascular and cerebrovascular, respiratory, and iron supplements. Products include BGM0504 injection, entecavir, pimecrolimus, and micafungin sodium for injection. The company generates revenue by providing API and preparation drugs such as BGM0504 injection and entecavir.

Current Investors

Lilly Asia Ventures, Oriza Holdings, Suzhou International Development Venture Capital Holding

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopolymers, Molecular Science, Genetics & Gene Therapy, Pharmaceuticals, Biomaterials

Website

www.bright-gene.com

Verticals

Manufacturing

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.